Use of the Interleukin-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection
Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
In this study Investigators propose to administer clazakizumab to patients with
life-threatening COVID-19 infection manifest by pulmonary failure and a clinical picture
consistent with a cytokine storm syndrome. This is a single-center randomized, double-blind,
placebo-controlled trial in which 30 patients will be enrolled and randomly assigned in a 1:1
ratio to two study arms that will receive clazakizumab at a dose of 25 mg or placebo.